Transcript of video
We meet weekly with our oncology team to discuss the importance of brain tumor diagnosis. We discuss the molecular class of the brain tumor. Dr. Sebastian Brandner, MD. We talk about the potential differential diagnosis. Dr. Anton Titov, MD. That is a team of radiologists, oncologists, neurologists, physiotherapists and clinical nurse specialists, psychologists, and the pathologists. So this team meets every week. It discusses new brain tumor patients. They come in with a presumed brain tumor diagnosis. Team reviews the brain imaging. It also reviews diagnosis of brain tumor in the patients. They had a brian biopsy and surgical operation. Then we put the pathological diagnosis. It may include molecular information. Dr. Sebastian Brandner, MD. Diagnosis may combine that with MRI. How does it fit the MRI? Is there a discrepancy? How to formulate a brain tumor treatment plan? In most cases the brain cancer treatment plan is straightforward. But sometimes we have discovered a certain type of mutation in brain tumor. Then the treatment plan might be more specific, more targeted. Brain cancer therapy might actually be highly specific to a mutation in the brain tumor. Changes are then directly applied to the patient’s treatment. So this is the sort of life cycle of a brain tumor specimen. That’s the part of the life cycle where the pathology contributes. It also shows you that we are part of the expert network. We are not actually hiding behind the microscope or behind the PCR machine. We are an integral part of a multidisciplinary team. It helps understanding and treatment of brain tumors. So this is very important. You highlighted the importance of multidisciplinary team. For best treatment correct now you have to apply P4 medicine. It is the personalized medicine. Dr. Sebastian Brandner, MD. Neuropathologist is at the forefront of that multidisciplinary team for brain cancer diagnosis. Team determines what is really best for that particular patient. I wouldn’t say neuropathologist is there in the forefront. There many types of cancer where the molecular pathology has had similar advances. Progress made over the last 5 – 10 years. It is soft-tissue tumors, breast cancer, hematology, and neuropathology. But all these disciplines have usually benefited from a massive advancement of molecular diagnostics. Dr. Anton Titov, MD. They were applied to the diagnostics of pathological brain tumor samples. Dr. Sebastian Brandner, MD. So that is a bridge between the science and the bedside. Correct, yes! Leading brain tumor diagnosis expert on importance of multidisciplinary team assessment of every patient with brain tumor.